The preclinical discovery of amyotrophic lateral sclerosis drugs

Bibliography

• Available from: http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_ALS.htm
   Google Scholar
• Bosco DA, Landers JE. Genetic determinants of Amyotrophic Lateral Sclerosis as therapeutic targets, [review]. CNS Neurol Disord Drug Targets 2010;9:779-90
   PubMed Web of Science ®Google Scholar
• Perry JJ, Shin DS, Tainer JA. Amyotrophic lateral sclerosis, [review]. Adv Exp Med Biol 2010;685:9-20
   PubMed Web of Science ®Google Scholar
• Bento-Abreu A, Van Damme P, Van Den Bosch L, The neurobiology of amyotrophic lateral sclerosis, [review]. Eur J Neurosci 2010;31:2247-65
   PubMed Web of Science ®Google Scholar
• Kuzma-Kozakiewicz M, Kwiecinski H. The genetics of amyotrophic lateral sclerosis, [review]. Neurol Neurochir Pol 2009;43:538-49
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, Riluzole, neuroprotection and amyotrophic lateral sclerosis, [review]. Curr Med Chem 2010;17:1942-199
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole, [review]. Neurology 1996;47:S233-41
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-8
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-11
   PubMed Web of Science ®Google Scholar
• Ticozzi N, Tiloca C, Morelli C, Genetics of familial Amyotrophic lateral sclerosis, [review]. Arch Ital Biol 2011;149:65-82
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann Rev Neurosci 2004;27:723-49
   PubMed Web of Science ®Google Scholar
• Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52:39-59
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/
   Google Scholar
• Miller RG, Mitchell JD, Lyon M, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), [review]. Cochrane Database Syst Rev 2007;24:CD001447
   Google Scholar
• Smith RA, Miller TM, Yamanaka K, Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290-6
   PubMed Web of Science ®Google Scholar
• Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13:568-80
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20
   PubMed Web of Science ®Google Scholar
• Deng HX, Biglio EH, Zhai H, Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol 2011;68:1057-61
   PubMed Web of Science ®Google Scholar
• Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011;5:1-5
   PubMed Web of Science ®Google Scholar
• Xia G, Benmohamed R, Kim J, Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem 2011;547:2409-21
   Google Scholar
• Benmohamed R, Arvanites AC, Kim J, Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12:87-96
   PubMed Web of Science ®Google Scholar
• Luo W, Sun W, Taldone T, Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 2010;5:24
   PubMed Web of Science ®Google Scholar
• Ray SS, Nowak RJ, Brown RH, Small molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA 2005;102(10):3639-44
   PubMed Web of Science ®Google Scholar
• Bao R, Lai CJ, Qu H, CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009;15:4046-57
   PubMed Web of Science ®Google Scholar
• Schmalbach S, Petri S. Histone deacetylation and motor neuron degeneration. CNS Neurol Disord Drug Targets 2010;9:279-84
   PubMed Web of Science ®Google Scholar
• d'Ydewalle C, Krishnan J, Chiheb DM, HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011;17:968-74
   PubMed Web of Science ®Google Scholar
• Markert CD, Kim E, Gifondorwa DJ, A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 2010;13:1081-5
   PubMed Web of Science ®Google Scholar
• Kim D, Nguyen MD, Dobbin MM, SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169-79
   PubMed Web of Science ®Google Scholar
• Shukla DK, Kaiser CC, Stebbins GT, Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett 2010;472:153-6
   PubMed Web of Science ®Google Scholar
• Schutz B, Reimann J, Dumitrescu-Ozimek L, The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005;25:7805-12
   PubMed Web of Science ®Google Scholar
• Shibata N, Yamamoto T, Hiroi A, Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 2010;30:353-60
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Chen J, Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005;191:331-6
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Grund H, Wingler K, Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010;8-13
   Web of Science ®Google Scholar
• Hill S, Hirano K, Shmanai VV, Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress. Free Radic Biol Med 2011;50:130-8
   PubMed Web of Science ®Google Scholar
• Appel SH, Zhao W, Beers DR, The microglial-motoneuron dialogue in ALS, [review]. Acta Myol 2011;30:4-8
   PubMedGoogle Scholar
• Di Giorgio FP, Boulting GL, Bobrowicz S, Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008;3:637-48
   PubMed Web of Science ®Google Scholar
• Available from: http://www.als.net/OurResearch/CurrentPipeline.aspx
   Google Scholar
• Mackenzie R, Kiernan M, McKenzie D, Hyperimmune goat serum for amyotrophic lateral sclerosis. J Clin Neurosci 2006;13:1033-6
   PubMed Web of Science ®Google Scholar
• Mackenzie RA. Follow-up study of hyper-immune goat serum (Aimspro) for amyotrophic lateral sclerosis (ALS). J Clin Neurosci 2009;16:1508-9
   PubMed Web of Science ®Google Scholar
• ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS. Amyotroph Lateral Scler 2010;11:571-3
   PubMed Web of Science ®Google Scholar
• Zhong Z, Ilieva H, Hallagan L, Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009;119:3437-49
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Weinreb O, Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 2010;21:361-71
   PubMed Web of Science ®Google Scholar
• Teichberg VI. GOT to rid the body of excess glutamate. J Cereb Blood Flow Metab 2011;31:1376-7
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Gruenbaum SE, Artru AA, The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 2009;21:235-41
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Tsai G, Kuncl RW, Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Van Kammen M, Levey AI, Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Dykes-Hoberg M, Pardo CA, Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-86
   PubMed Web of Science ®Google Scholar
• Bendotti C, Tortarolo M, Suchak SK, SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 2001;79:737-46
   PubMed Web of Science ®Google Scholar
• Colton CK, Kong Q, Lai L, Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen 2010;15:653-62
   PubMed Web of Science ®Google Scholar
• Xing X, Chang LC, Kong Q, Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett 2011;21:5774-7
   PubMed Web of Science ®Google Scholar
• Diogenes MJ, Outeiro TF. Neurotrophic factors as a protective strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 2010;9:754-63
   PubMed Web of Science ®Google Scholar
• Yang T, Knowles JK, Lu Q, Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One 2008;3:e3604
   Google Scholar
• Hellman M, Arumae U, Yu LY, Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons, Exp. Neurol 2011;228:99-108
   Google Scholar
• Rizvanov AA, Guseva DS, Salafutdinov II, Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp Biol Med (Maywood) 2011;236:91-8
   PubMed Web of Science ®Google Scholar
• Visanji NP, Orsi A, Johnston TH, PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008;22:2488-97
   PubMed Web of Science ®Google Scholar
• Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders,. Physiol Genomics 2011;43:571-80
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Im WS, Altered microRNA regulation in Huntington's disease models. Exp Neurol 2011;227:172-9
   PubMed Web of Science ®Google Scholar
• Wang H, Liu J, Zong Y, miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-beta type II receptor. Brain Res 2010;1357:166-74
   PubMed Web of Science ®Google Scholar
• Haramati S, Chapnik E, Sztainberg Y, miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010;107:13111-16
   PubMed Web of Science ®Google Scholar
• Williams AH, Valdez G, Moresi V, MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009;326:1549-54
   PubMed Web of Science ®Google Scholar
• Maragakis NJ. Stem cells and the ALS neurologist. Amyotroph Lateral Scler 2010;11:417-23
   PubMed Web of Science ®Google Scholar
• Silani V, Calzarossa C, Cova L, Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement? CNS Neurol Disord Drug Targets 2010;9:314-24
   PubMed Web of Science ®Google Scholar
• Mazzini L, Vercelli A, Ferrero I, Stem cells in amyotrophic lateral sclerosis: state of the art. Expert Opin Biol Ther 2009;9:1245-58
   PubMed Web of Science ®Google Scholar
• Fornai F, Meininger V, Silani V. Future therapeutical strategies dictated by pre-clinical evidence in ALS. Arch Ital Biol 2011;149:169-74. 81
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Fujiwara N, Ido A, Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010;69:1044
   PubMed Web of Science ®Google Scholar
• Angelov DN, Waibel S, Guntinas-Lichius O, Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003;100:4790-5
   PubMed Web of Science ®Google Scholar
• Rutkove S. Electrical impedance myography as a biomarker for ALS. Lancet Neurol 2009;8:226; author reply 227
   PubMed Web of Science ®Google Scholar
• Baltadzhieva R, Gurevich T, Korczyn AD. Autonomic impairment in amyotrophic lateral sclerosis. Curr Opin Neurol 2005;18:487-93
   PubMed Web of Science ®Google Scholar
• Siddique N, Siddique T. Genetics of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008;19(3):429-39
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21
   PubMed Web of Science ®Google Scholar
• Bull ND, Martin KR. Towards stem cell-based therapies for retinal neurodegenerative diseases. Stem Cells 2011;676
   Google Scholar
• Dyson SC, Barker RA. Cell-based therapies for Parkinson's disease. Expert Rev Neurother 2011;11:831-44
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov, identifier no. NCT00875654
   Google Scholar
• Harting MT, Jimenez F, Xue H, Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009;110:1189-97
   PubMed Web of Science ®Google Scholar
• Turner MR, Modo M. Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opin Med Diagn 2010;4:483-96
   PubMedGoogle Scholar
• Agosta F, Chio A, Cosottini M, The present and the future of neuroimaging in amyotrophic lateral sclerosis, [review]. AJNR Am J Neuroradiol 2010;31:1769-77
   PubMed Web of Science ®Google Scholar
• Pradat PF, Dib M. Biomarkers in amyotrophic lateral sclerosis: facts and future horizons, [review]. Mol Diagn Ther 2009;13:115-25
   PubMed Web of Science ®Google Scholar
• Turner MR, Kiernan MC, Leigh PN, Biomarkers in amyotrophic lateral sclerosis, [review]. Lancet Neurol 2009;8:94-109
   PubMed Web of Science ®Google Scholar
• Sussmuth SD, Brettschneider J, Ludolph AC, Biochemical markers in CSF of ALS patients, [review]. Curr Med Chem 2008;15:1788-801
   PubMed Web of Science ®Google Scholar
• Wegorzewska I, Bell S, Baloh RH, TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009;106:18809-14
   PubMed Web of Science ®Google Scholar